Novo Nordisk (NVO) said Monday a study of its Rybelsus oral semaglutide as an adjunct to the standard of care for preventing major adverse cardiovascular events met its primary goal.
The drugmaker said the study showed a statistically significant and superior reduction in major adverse cardiovascular events of 14% for people treated with oral semaglutide compared to placebo.
The study enrolled 9,650 people with type 2 diabetes and established cardiovascular disease and/or chronic kidney disease.
Novo Nordisk said it expects to file for regulatory approval of a label expansion for Rybelsus in the US and EU around the turn of the year.
Price: 117.18, Change: -0.91, Percent Change: -0.77
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。